Press release
Menlo Park, CA
November 2, 2023
Orca Bio to Present Positive Clinical Data on its Novel High-Precision Cell Therapies at the 65th American Society of Hematology Annual Meeting
The first oral presentation will demonstrate the performance of Orca-T in patients over 55 years of age compared with younger patients
A second oral presentation will highlight Orca-Q, Orca Bio’s high-precision cell therapy for patients with haploidentical donors
Additional poster presentations include outcomes in patients with high-risk myelodysplastic syndrome treated with Orca-T and results of Orca-T in patients undergoing reduced intensity conditioning
MENLO PARK, CA, November 2, 2023 – Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, today announced that new data will be presented at the American Society of Hematology (ASH) Annual Meeting from December 9-12 in San Diego, CA. Specifically, an oral presentation will highlight the outcomes of myeloablative Orca-T, Orca Bio’s lead investigational high-precision cell therapy, in patients over the age of 55. A second oral presentation will share updated results in an expanded group of patients with haploidentical donors treated with Orca Bio’s second investigational high-precision cell therapy, Orca-Q.
Orca Bio will also present two posters highlighting the results of patients with high-risk myelodysplastic syndrome who were treated with Orca-T, and the outcomes of patients treated with Orca-T who received reduced intensity conditioning.
The ASH abstracts are now available at www.hematology.org. Details of the Orca Bio presentations follow:
Oral Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia
Title: Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies
Abstract Number: 230
Date and Time: Saturday, December 9, 2023 at 2:15 PM PT
Location: Marriott Marquis, Marriott Grand Ballroom 5-6
Oral Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas
Title: Safety and Efficacy of Orca-Q with Haploidentical Donors for the Treatment of Advanced Hematologic Malignancies Without the Use of Post-Transplant Cyclophosphamide
Abstract Number: 773
Date and Time: Monday, December 11, 2023 at 11:30 AM PT
Location: San Diego Convention Center, Room 6CF
Poster Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies
Title: High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T
Abstract Number: 2230
Date and Time: Saturday, December 9, 2023 at 5:30 PM PT
Location: San Diego Convention Center, Halls G-H
Poster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
Title: Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus
Abstract Number: 3560
Date and Time: Sunday, December 10, 2023 at 6:00 PM PT
Location: San Diego Convention Center, Halls G-H
About Orca-T
Orca-T is an investigational high-precision allogeneic cell therapy for the treatment of multiple hematological malignancies. Orca-T includes infusions containing regulatory T-cells, CD34+ stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors. Orca-T is currently being evaluated in a pivotal Phase 3 clinical trial at leading transplant centers across the U.S. and has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration.
About Orca-Q
Orca-Q is an investigational high-precision allogeneic cell therapy designed to treat hematological malignancies in patients with haploidentical donors. Orca-Q is a proprietary composition of stem cells combined with specific T-cell subsets derived from healthy donors and engineered by Orca Bio’s high-precision platform. Orca-Q has the potential to improve patient outcomes and reduce the risks of toxicities without the use of post-transplant cyclophosphamide (PTCy) in patients unable to identify a full human leukocyte antigen (HLA) match.
About Orca Bio
Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders. Our investigational products are designed to safely replace a patient’s diseased blood and immune system with a healthy one, delivering significantly better outcomes with dramatically fewer risks than the standard of care. Our manufacturing platform uses single-cell precision to create proprietary, uniquely-defined products that have the potential to transform allogeneic cell therapy. At Orca Bio, our mission is to make curative cell therapies both more effective and safer, and in doing so, push past the field’s current boundaries and redefine its future. For more information, visit www.orcabio.com and follow Orca Bio on Twitter: @OrcaBio.